News – Page 35 – Alligator Bioscience

2020-11-16

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Lund, Sweden and Seattle, WA – November 16, 2020 – Alligator Bioscience (“Alligator”) (Nasdaq Stockholm: ATORX), a biotechnology company dev ...

2020-11-09

Three projects showcased – ATOR-1015, ALG.APV-527 and Neo-X-Prime – Lund, Sweden, November 9, 2020 – Alligator Bioscience (N ...

2020-11-05

Strong benchmark to competitor CD40 antibodies Lund, Sweden, November 5, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announc ...

2020-10-27

Regulatory

Lund, Sweden, October 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced additional positive interim safety data from ...

2020-10-22

Regulatory

Encouraging clinical safety data for ATOR-1017 The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented ...

2020-10-22

Regulatory